This was published under the 2010 to 2015 Conservative and Liberal Democrat coalition government
Impact Assessment on the Introduction of the New Medicine Service.
PDF, 643KB, 24 pages
This file may not be suitable for users of assistive technology. Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email email@example.com . Please tell us what format you need. It will help us if you say what assistive technology you use.
The New Medicine Service (NMS) aims to help people prescribed a new medicine for certain Long Term Conditions (LTC) to manage their LTC and to improve their medication adherence through providing further clinical support at the outset of taking new medication in keeping with overall government health policy to involve patients in shared decision making and to optimise medicines use. The intended effects are to improve patients’ medicines adherence, patients’ understanding of medicines, patients’ engagement with their condition, and health outcomes; as well as reducing health inequalities, and medicines wastage. By achieving the above, it is anticipated that cost savings can also be generated within the NHS.
Published: 23 September 2011
From: Department of Health